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Brain nicotinic acetylcholine receptors (nAChRs), a heterogeneous family of pentameric 
acetylcholine-gated cation channels, have been suggested as molecular targets for 
the treatment of alcohol abuse and dependence. Here, we examined the effect of the 
competitive nAChR antagonist UFR2709 on the alcohol consumption of high-alcohol-
drinking UChB rats. UChB rats were given free access to ethanol for 24-h periods in 
a two-bottle free choice paradigm and their ethanol and water intake were measured. 
The animals were i.p. injected daily for 17 days with a 10, 5, 2.5, or 1 mg/kg dose of 
UFR2709. Potential confounding motor effects of UFR2709 were assessed by examining 
the locomotor activity of animals administered the highest dose of UR2709 tested (10 mg/
kg i.p.). UFR2709 reduced ethanol consumption and ethanol preference and increased 
water consumption in a dose-dependent manner. The most effective dose of UFR2709 
was 2.5 mg/kg, which induced a 56% reduction in alcohol consumption. Administration 
of UFR2709 did not affect the weight or locomotor activity of the rats, suggesting that its 
effects on alcohol consumption and preference were mediated by specific nAChRs.
Keywords: alcohol dependence, ethanol, UChB rats, nAChR antagonism, voluntary ethanol drinking
INTRODUCTION
Alcohol is the most commonly abused legal substance and alcoholism is a serious public health 
problem worldwide (WHO, 2014). Several lines of evidence have identified neuronal nicotinic 
acetylcholine receptors (nAChRs) in the mesocorticolimbic-dopamine (DA) system as being 
involved in alcoholism (Madden and Heath, 2002; John et al., 2003; Dani and Harris, 2005; Falk et al., 
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2006). Consistent with this view, nAChR ligands reduce ethanol 
consumption in various animal models and humans (Chatterjee 
and Bartlett, 2010; Rahman et al., 2015).
nAChRs belong to the pentameric ligand-gated ion channel 
superfamily. The most abundant nAChRs in the brain are the 
heteromeric α4β2 and homomeric α7 subtypes (Gotti et al., 
2006; Albuquerque et al., 2009). Other heteromeric nAChRs 
present in the brain include the α4β2α5, α6β2β3, α4β2α6, α4β4, 
α3β4 and α3β2 subtypes, but these are less abundant and/or 
have a more restricted distribution (Gotti et al., 2006). Ethanol 
intake appears to involve a variety of nAChR subtypes (Joslyn 
et al., 2008; Saccone et al., 2009; Taslim and Saeed Dar, 2011). 
α7 (Kamens et al., 2010a) and α3β4 nAChRs (Chatterjee et al., 
2011; Miller et al., 2019) have both been implicated in ethanol 
intake, and receptors containing the α5 nAChR subunit are 
thought to be associated with the sedative effects of ethanol 
(Santos et al., 2013). Furthermore, the α4β2 nAChR subtype 
may be involved in alcohol intake due to its role in the brain’s 
reward system. Ethanol activates the mesolimbic-DA system, 
inducing the release of DA in the nucleus accumbens from 
projections that arise in the ventral tegmental area (VTA) 
(Gessa et al., 1985; Di Chiara and Imperato, 1988). VTA 
dopaminergic neurons primarily express the α4β2 nAChR 
subtype, but also express nAChRs exhibiting combinations 
of α5 and α6 subunits (Klink et al, 2001; Azam et al., 2002). 
These nAChRs are activated by cholinergic inputs from the 
laterodorsal tegmental and pedunculopontine tegmental nuclei 
(Oakman et al., 1995; Jerlhag et al., 2012; Xiao et al., 2016). 
Interestingly, voluntary ethanol consumption increases ACh 
levels in the VTA and promotes DA overflow in the nucleus 
accumbens in rats (Larsson et al., 2005). This establishes a 
cholinergic-dopaminergic reward axis (Xiao et al., 2016), which 
is affected by ethanol (Engel and Jerlhag, 2014).
Partial agonists of nAChRs such as cytisine (Papke and 
Heinemann, 1993; Rollema et al., 2010) and varenicline (Coe 
et al., 2005; Rollema et al., 2007) have been shown to decrease 
ethanol intake in rodents after a single dose or short-term 
administration (Steensland et al., 2007; Kamens et al., 2010b; 
Sajja and Rahman, 2011). Indeed, we confirmed the effects of 
varenicline and cytisine on alcohol intake in alcohol-preferring 
University of Chile (UChB) rats (Sotomayor-Zárate et al., 2013). 
These animals have been selectively bred for over 90 generations 
for their ethanol preference and are considered suitable models 
of alcohol dependence (Mardones and Segovia-Riquelme, 1983; 
Quintanilla et al., 2006; Tampier and Quintanilla, 2010). Given 
that partial agonists display competitive antagonistic effects 
in the presence of a full agonist, the effects of cytisine and 
varenicline on alcohol intake may stem from their antagonistic 
effects rather than from their partial activation of nAChRs. 
Consistent with this possibility, we showed that administration 
of erysodine, a competitive nAChR inhibitor, induced a marked 
decrease in alcohol intake in UChB rats (Quiroz et al., 2018). 
To further explore the efficacy of nAChR inhibitors in reducing 
alcohol intake, we assessed the effects of UFR2709 [(S)-1-
methylpyrrolidin-2-yl) methyl benzoate], a recently described 
competitive nAChR antagonist (Faundez-Parraguez et al., 2013), 
on the maintenance of ethanol intake by alcohol-preferring 
UChB rats. Here, we show that UFR2709 reduces ethanol intake 
in a dose-dependent manner without affecting body weight or 
locomotor activity.
MATERIAls AND METhODs
Drugs and Drinking solutions
UFR2709-HCl (M.W. 255.74 g/mol) was synthesized as 
previously reported (Faundez-Parraguez et al., 2013). The 
structure of UFR2709-HCl was confirmed by one- and two-
dimensional 1H and 13C NMR analyses. Nicotine ditartrate was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). All other 
reagents used were of analytical grade. The volume of injection (1 
ml/kg) was adjusted to body weight to achieve the desired dose 
of UFR2709-HCl. Ethanol solutions (10% v/v) were prepared by 
mixing absolute ethanol (Merck, Darmstadt, Germany) with tap 
water. Ethanol concentration was chosen based on prior studies 
using UChB rats (Mardones and Segovia-Riquelme, 1983; 
Quintanilla et al., 2006).
Animals
The experiments were carried out in male Wistar-UChB rats 
(n = 37). The UChB rat line has been bred for over 90 generations 
to ingest 10% ethanol solution in preference to water (Mardones 
and Segovia-Riquelme, 1983; Quintanilla et al., 2006). Thus, 
these animals are considered suitable models of alcoholism and 
are used to screen medications to treat alcoholism (Quintanilla 
et al., 2006). UChB rats weighing between 240 and 280 g were 
housed individually (for ethanol consumption experiments) or 
in trios (for locomotor activity experiments) in polycarbonate 
cages in temperature- and humidity-controlled conditions under 
a regular 12-h light-dark cycle (lights off at 19:00 h) with free 
access to food and water. All alcohol consumption experiments 
were performed at the Faculty of Medicine, Universidad de Chile.
All animal experiments were performed in accordance with 
ARRIVE guidelines (Kilkenny et al., 2010) and approved by the 
“Animal Experimentation Ethics Committee of the Universidad 
de Chile”.
Effect of Different Doses of UFR2709 on 
the Maintenance of Ethanol Intake by 
UChB Rats
The ethanol preference of UChB rats administered different 
doses of UFR2709 was assessed using a two-bottle free choice 
experimental paradigm, as previously described (Mardones 
and Segovia-Riquelme, 1983; Quintanilla et al., 2006; Tampier 
and Quintanilla, 2010; Sotomayor-Zárate et al., 2013). Twenty-
five UChB rats were housed in individual cages and subjected 
to a homecage two-bottle free choice regimen between ethanol 
10%  v/v and distilled water with continuous access (24 h/day). 
The positions of the bottles were alternated daily to avoid 
potential position preference. After 20 days, a stable plateau of 
ethanol consumption was reached, and the final three drinking 
days were averaged to obtain the mean voluntary ethanol 
consumption of each rat. The rats were then randomly divided 
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into five groups (n = 5 per group), and a single i.p. injection of 
UFR2709-HCl (1, 2.5, 5, or 10 mg/kg) or saline was administered 
for 17 days at 15:00 h. After the treatment period, all UChB rats 
were maintained under the 24-h continuous access two-bottle 
free choice paradigm for three additional days. The animals were 
allowed ad libitum access to food. The weight and ethanol and 
water intake of the animals were recorded at 14:00 h each day and 
expressed as g ethanol/kg/day and mL water/kg/day, respectively.
Effect of UFR2709 on locomotor Activity
Locomotor activity was assessed using the open-field test, as 
previously described (Rivera-Meza et al., 2014). The open-field 
apparatus consisted of a black polycarbonate chamber (43 × 43 × 
43 cm), the floor of which was marked with lines (length: 14.3 
cm) forming a 3 × 3 grid. To study the effects of UFR2709 on 
locomotor activity, 12 ethanol-naïve UChB rats were randomly 
assigned to two groups and administered a 10 mg/kg dose (i.p.) 
of UFR2709 (n = 6) or an equivalent volume of saline (n = 6) 
(1 mL/kg). After 30 min of UFR2709 or saline administration, 
the animals were individually placed in the center of the open-
field apparatus, and their locomotor activity was recorded for 30 
min. Locomotor activity was recorded by a digital camera which 
was fixed above the test chamber and connected to a computer in 
another room. The apparatus was wiped and cleaned with water 
after each trial. Horizontal locomotor activity was expressed as 
activity units (AUs) per 5 min. An AU was defined as complete 
crossing from one square to another. The number of times of 
vertical rear per 5 min and the time (in s) spent in grooming 
behavior were also measured.
Determination of Octanol-Buffer Distribution 
Coefficient of UFR2709 At ph 7.4
Octanol-buffer distribution coefficient at pH 7.4 (Log D7.4) values 
were determined using the shake-flask method (Andrés et al., 
2015). Briefly, 5 mg of UFR2709-HCl and nicotine were added to 
5 mL of 50 mM phosphate buffer (pH 7.4) and 5 mL of n-octanol 
(water saturated) in a glass vial. The sample vial was mixed by 
vortexing and then incubated to equilibrium for 24 h at 25°C. 
After equilibration, the phases were separated and the compounds 
were measured by UV spectroscopy at a wavelength of 232 nm 
for UFR2709-HCl and 257 nm for nicotine using calibration 
curves. The logarithm of the quotient of the concentrations in 
the organic and aqueous phases (Log D7.4) was calculated. Values 
correspond to the mean ± SEM of five independent assays.
statistical Analysis
Differences between UFR2709- and saline-treated animals 
were analyzed using two-way ANOVA with Tukey´s multiple 
comparison test (Figures 1 and 2). One-way ANOVA followed 
by Tukey’s post hoc test was used to analyze the effect of 17 
days of saline or UFR2709 administration on average ethanol 
intake (Figure 3). The time-course of horizontal and vertical 
locomotor activity and grooming behavior was recorded every 
5 min throughout the 30 min test period. Data were analyzed 
using two-way ANOVA followed by Bonferroni’s post hoc test 
to compare the effects of saline and UFR2709 (10 mg/kg, i.p.) 
(Figure 4). Data are expressed as mean ± SEM. Statistical analyses 
were performed using Graph Pad Prism 8.0 software (Graph 
Pad Software, San Diego, CA, USA), and the level of statistical 
significance was set at P < 0.05.
REsUlTs
Effect of UFR2709 on the Maintenance of 
Ethanol Intake by UChB Rats
To determine the effect of different doses of UFR2709 on the 
maintenance of voluntary ethanol intake, alcohol-preferring UChB 
rats were given a free choice between 10% v/v ethanol and water for 
20 days. At day 20 of ethanol access, animals were administered a 
1, 2.5, 5, or 10 mg/kg dose of UFR2709 or saline each day for 17 
consecutive days. The baseline levels of ethanol consumption for 
all groups correspond to the average ethanol intake during the last 
3 days before the treatment period. Two-way ANOVA with Tukey’s 
multiple comparison test with dose and day as factors showed that 
all UFR2709 doses significantly reduced ethanol intake (Figure 1) 
in comparison to saline (interaction [F(76,400) = 2.992, P < 0.0001]; 
days [F(19,400) = 10.20, P < 0.0001]; doses [F(4,400) = 179.5, P < 
0.0001]). In addition, all UFR2709 doses significantly increased 
water intake (Figure 2) in comparison to saline (interaction 
[F(76,400) = 2.244, P < 0.0001]; days [F(19,400) = 6.708, P < 0.0001]; 
doses [F(4,400) = 77.82, P < 0.0001]).
Figure 3 shows the total average ethanol intake across the 
treatment period of the groups administered different doses of 
UFR2709. One-way ANOVA indicated that UFR2709 treatment 
significantly reduced average ethanol intake [F(4,80) = 50.18, P < 
0.0001], and Tukey’s post hoc test confirmed that all UFR2709 
doses significantly reduced average ethanol intake compared to 
saline. Administration of a 2.5 mg/kg dose of UFR2709 induced 
a 56.9% reduction in alcohol intake. All other UFR2709 doses 
induced smaller reductions in alcohol intake: 1, 5, and 10 
mg/kg doses induced 33.4%, 35.2%, and 31.3% reductions, 
respectively. Administration of UFR2709 did not affect body 
weight compared to saline, and the rats exhibited normal 
increases in body weight during the course of this study (data 
shown in Supplementary Material).
Effects of UFR2709 on locomotor Activity
To determine if differences in alcohol consumption could be 
attributed to decreased locomotor activity, we assessed the 
locomotor activity of UFR2709- and saline-treated animals. 
For these experiments, animals were administered the highest 
dose of UFR2709 (10 mg/kg i.p) used in the aforementioned 
experiments. Figure 4A shows the time-course of horizontal 
locomotor activity measured every 5 min during the 30-min test 
period of UChB rats treated with UFR2709 (10 mg/kg) or saline. 
Two-way ANOVA showed that UFR2709 treatment did not 
affect locomotor activity compared to saline (treatment [F(1,60) = 
3.77, P = 0.057]). Figure 4B shows the time-course of vertical 
activity measured every 5 min during the 30-min test period of 
UChB rats treated with UFR2709 (10 mg/kg) or saline. Two-way 
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ANOVA showed that UFR2709 treatment did not significantly 
affect the vertical activity of the animals (treatment [F(1,60) = 
2.47, P = 0.121]). Figure 4C shows the time-course of grooming 
activity measured every 5 min during the 30-min test period of 
UChB rats treated with UFR2709 (10 mg/kg) or saline. Two-way 
ANOVA showed that UFR2709 treatment did not significantly 
affect the grooming activity of the animals (treatment [F(1,60) = 
0.04, P = 0.845]).
Distribution Coefficient
Prior to the experimental determination of Log D7.4, we 
theoretically calculated the cLogP value of UFR2709. The 
theoretical cLogP value for UFR2709 was 2.5, indicating that this 
drug should be able to access the central nervous system (CNS). 
As shown in Table 1, UFR2709 had an experimental LogD7.4 value 
of 1.14 ± 0.03 (assessed by the shake-flask method), which was 
higher than that obtained for nicotine (0.13 ± 0.01) (Zhu et al., 
2002; Andrés et al., 2015), confirming its capacity to access the 
CNS. We also calculated the cLogP values of molecules capable 
of crossing the blood-brain barrier (BBB), namely imipramine, 
fluoxetine, methylphenidate, mecamylamine, and erysodine, 
obtaining values of 4.32, 4.27, 2.16, 2.38, and 1.40, respectively.
DIsCUssION
Here, we report the effects of UFR2709, a non-selective competitive 
nAChR antagonist, on the ethanol consumption of high-alcohol-
drinking UChB rats (Mardones and Segovia-Riquelme, 1983; 
Quintanilla et al., 2006; Tampier and Quintanilla, 2010). Our 
results show that all doses of UFR2709 tested elicited a reduction 
in voluntary ethanol consumption and a concomitant increase in 
water intake. However, the effect of UFR270 on reducing alcohol 
intake was bell-shaped—its efficacy increased from 1 mg/kg to 
2.5 mg/kg and then reduced at higher concentrations (5 and 
10 mg/kg). This gradual loss of effectiveness may be due to the 
development of tolerance, which we have previously observed 
with the partial agonists cytisine and varenicline in UChB rats 
(Sotomayor-Zárate et al., 2013).
FIgURE 1 | Influence of 17 days of UFR2709 treatment on the voluntary ethanol intake of high-alcohol-drinking UChB rats under a 24-h access two-bottle free 
choice paradigm. The baseline ethanol consumption of each experimental group is the average ethanol intake during the last 3 days before the treatment period. 
For 17 consecutive days, rats (n = 5 per group) were administered a single i.p. injection of UFR2709 (1, 2.5, 5, or 10 mg/kg/day) or saline (1 mL/kg/day) at 15:00 
h, and ethanol consumption was recorded at 14:00 h the next day. Ethanol consumption data are expressed as mean ± SEM (g/kg/day). Two-way ANOVA with 
Tukey’s multiple comparison test was used to analyze the effect of UFR2709 treatment on ethanol consumption (P < 0.0001). Arrows indicate the time points of 
UFR2709 (1, 2.5, 5, or 10 mg/kg) or saline (1 mL/kg) administration via i.p. injection. ****0.0001.
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The effects of UFR2709 on alcohol intake may have resulted 
from UFR2709 reducing locomotor activity via the inhibition 
of muscle nAChRs. This is unlikely, however, as administration 
of a single 10 mg/kg dose of UFR2709 to ethanol-naïve UChB 
rats had no effect on the time-course of horizontal, vertical, or 
grooming activity. Signs of discomfort or changes in body weight 
were not observed in the alcohol-exposed animals, suggesting 
that the effects of UFR2709 on alcohol intake were due to the 
inhibition of nAChRs in the mesocorticolimbic-DA system.
Our results support the view that nAChR inhibition in the 
mesocorticolimbic-DA system reduces ethanol consumption. 
Previous reports have indicated that systemic administration 
of mecamylamine, a non-competitive and non-selective 
nAChR antagonist that crosses the BBB (Bacher et al., 2009), 
reduces voluntary ethanol consumption in rodents (Blomqvist 
et al., 1996; Ford et al., 2009; Farook et al., 2009). Importantly, 
hexamethonium, a nAChR antagonist that does not cross the 
BBB, has no effect on ethanol intake (Blomqvist et al., 1996). 
Therefore, given that the Log D7.4 value of UFR2709 is between 
1 and 3, which, according to the literature, is the optimum range 
for CNS penetration (Andrés et al., 2015), we suggest that it acts 
in the CNS. Furthermore, microdialysis experiments conducted 
in the striatum indicated that UFR2709 did not induce DA 
release, but rather elicited a slight decrease in basal DA levels, 
although this change was not statistically significant (data shown 
in Supplementary Material).
Even though UFR2709 displays higher affinity for α4β2 
nAChRs than for α7 nAChRs (Faundez-Parraguez et al., 2013), 
the fact that ACh-induced currents are potentiated by ethanol 
(Aistrup et al., 1999; Cardoso et al., 1999) indicates that some 
other nAChR subtype(s) may be involved in the actions of 
UFR2709. Inhibition of α7 nAChRs does not modify the 
behavioral and neurochemical effects of ethanol (Larsson et al., 
2002). However, α-conotoxin-MII, an antagonist of α3β2- and 
α6-containing nAChRs, blocks ethanol-associated conditioned 
reinforcement (Löf et al., 2007), and reduces ethanol-induced 
DA efflux and voluntary ethanol consumption in mice and rats 
(Larsson et al., 2004), suggesting that these nAChR subtypes 
may be involved in neurochemical effects of ethanol. Moreover, 
α6 subunit-containing nAChRs are predominantly expressed 
FIgURE 2 | Influence of 17 days of UFR2709 treatment on the water intake of high-alcohol-drinking UChB rats under a 24-h access two-bottle free choice 
paradigm. The baseline water consumption of each experimental group is the average water intake during the last three days before the treatment period. For 
17 consecutive days, rats (n = 5 per group) were administered a single i.p. injection of UFR2709 (1, 2.5, 5, or 10 mg/kg/day) or saline (1 mL/kg/day) at 15:00 h, 
and water intake was recorded at 14:00 h the next day. Water intake data are expressed as mean ± SEM (mL/kg/day). Two-way ANOVA with Tukey’s multiple 
comparison test was used to analyze the effect of UFR2709 treatment on water intake (P < 0.0001). Arrows indicate the time points of UFR2709 (1, 2.5, 5, or 10 
mg/kg) or saline (1 mL/kg) administration via i.p. injection. ****0.0001.
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by dopaminergic neurons of the mesocorticolimbic-DA system 
(Klink et al., 2001; Champtiaux et al., 2002), and ethanol 
induces an α6 subunit-dependent increase in the firing rate of 
dopaminergic neurons in the VTA (Liu et al., 2013). Our study 
does not indicate the nAChR subtypes implicated in the effects 
of UFR2709, but clearly demonstrates that nAChR inhibition 
reduces ethanol intake. This supports the idea that nAChRs could 
be used as therapeutic targets for the treatment of alcohol abuse.
CONClUsION
In summary, UFR2709 reduces ethanol consumption in a dose-
dependent manner. The effects of the highest doses of UFR2709 
(5 and 10 mg/kg) were less sustained than those of the lower 
doses, suggesting that high doses induced drug tolerance. On 
the other hand, the 2.5 mg/kg dose of UFR2709 was the most 
potent and therapeutically effective, eliciting a long-lasting effect. 
Remarkably, this effect continued for at least 2 days after the last 
administration. Additionally, our results show that UFR2709 
does not affect locomotor activity or body weight. Thus, our 
data give further support to the idea that UFR2709, a nAChR 
FIgURE 3 | Average reduction in ethanol intake induced by 17 consecutive 
days of UFR2709 (1, 2.5, 5, 10 mg/kg/day i.p.) or saline (1 mL/kg i.p.) 
administration. Each bar represents the average ethanol intake of high-
alcohol-drinking UChB rats (n = 5 per group) during the 17-day treatment 
period. Data are expressed as mean ± SEM (g/kg/day). One-way ANOVA 
followed by Tukey’s post hoc test was used to compare the saline and 
UFR2709 groups (***P < 0.001 vs. saline group; $P < 0.001 vs. 2.5 mg/
kg UFR2709 group). The number inside each bar indicates the percentage 
reduction in ethanol intake compared to the saline group.
FIgURE 4 | Effect of UFR2709 (10 mg/kg i.p.) or saline (1 mL/kg i.p.) administration on the locomotor activity and grooming behavior of UChB rats. Twelve rats 
were administered UFR2709 (n = 6) or saline (n = 6) 30 min before locomotor activity was assessed. (A) Time-course of horizontal activity per 5 min, presented 
as the number of arbitrary units (AU) of activity per 5 min. Results are expressed as the mean ± SEM. (B) Time-course of vertical activity per 5 min, presented as 
the number of vertical rears per 5 min. Results are expressed as the mean ± SEM. (C) Time-course of grooming activity per 5 min, presented as the time (s) of 
grooming activity per 5 min. Results are expressed as the mean ± SEM. Two-way ANOVA followed by Bonferroni’s post hoc test was used to compare the saline 
and UFR2709 groups.
TABlE 1 | Theoretical (cLogP) and experimental lipophilicity of UFR2709 and 
Nicotine were determined using the octanol-buffer distribution coefficient at pH 
7.4 (Log D7.4).
Compound clogP log D7.4 Reference log D7.4
UFR2709 2.15 1.14 ± 0.03. –
Nicotine 0.93 0.13 ± 0.01 0.41a
Data represent the mean ± SEM of five experiments. aZhu et al., 2002.
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antagonist, may be a novel therapeutic agent for the treatment 
of alcoholism, and highlight nAChRs as potential targets for the 
design of drugs aimed to reduce ethanol intake.
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